Our understanding of the molecular basis for monogenic disordershas made remarkable progress during the past 30 years, leadingto new insights into disease mechanisms, a huge increase inthe range of prenatal and presymptomatic diagnostic tests, andalthough still uncommon, some mechanism-based therapies forgenetic diseases. However, for most diseases, the nature ofan inherited predisposition is more complex. If the geneticvariants underlying complex disease could be identified, theytoo might bring clinical benefits. Such progress might occur,for example, through the identification of new disease pathwaysthat could be exploited by new pharmacotherapy or by more effective. . . [Full Text of this Article]
Source Information
From the Department of Clinical Biochemistry and Medicine, University of Cambridge, Addenbrooke's Hospital (S.O.); and the Medical Research Council Epidemiology Unit (N.J.W.) — both in Cambridge, United Kingdom.
This article has been cited by other articles:
Burton, P. R, Hansell, A. L, Fortier, I., Manolio, T. A, Khoury, M. J, Little, J., Elliott, P.
(2009). Size matters: just how big is BIG?: Quantifying realistic sample size requirements for human genome epidemiology. Int J Epidemiol
38: 263-273
[Abstract][Full Text]
Kulkarni, S. R., Fall, C. H.D., Joshi, N. V., Lubree, H. G., Deshpande, V. U., Pasarkar, R. V., Bhat, D. S., Naik, S. S., Yajnik, C. S.
(2007). Determinants of Incident Hyperglycemia 6 Years After Delivery in Young Rural Indian Mothers: The Pune Maternal Nutrition Study (PMNS). Diabetes Care
30: 2542-2547
[Abstract][Full Text]
Previous
